Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61Q17/005—Antimicrobial preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
  • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q15/00—Anti-perspirants or body deodorants

Definitions

• the present invention relates to a bacteriostatic composition and method of combating growth of certain Gram-positive skin bacteria.
• cosmetic preparations which either reduce perspiration at the skin surface (antiperspirant) or which substantially destroy the natural bacterial flora of the skin (bacteriocidal deodorants). In both cases significant disruptions of natural conditions at the skin surface occur.
• the deodorants which are of particular interest here practically always comprise strongly halogenated phenol compounds, the use of which is according to most recent knowledge not necessarily without problem, and in view of their strong bacteriocidal activity destroy practically all bacterial skin flora.
• Products are therefore being sought which prevent or strongly diminish growth of bacterial flora of the skin, which are present also after conventional bathing, which products however do not further disturb the natural equilibrium of biological procedures at the surface of the skin.
• farnesol (3,7,11-trimethyl-dodeca-2,6,10-trien-1-ol) which occurs widely in nature, is higly effective in inhibiting the growth of odor-forming bacterial flora of the skin at relatively low concentrations, without influencing the biological equilibrium at the skin surface.
• the invention accordingly relates to the use of farnesol as a bacteriostatic agent, or a component thereof, in cosmetic products for application to the human skin.
• farnesol has long been known to be present in ether oils, and experimentation has been carried out on the bacteriostatic or bacteriocidal activity of such ether oils, the bacteriostatic activity of the natural substance farnesol has remained unrecognized. This is no doubt to be attributed to the fact that farnesol is normally present in the ether oils in extremely low amounts and that the concentration, at which a bacteriostatic activity is exhibited, has not been reached.
• a farnesol concentration of 0.25% is sufficient in all circumstances.
• the minimum inhibition concentration to achieve a total inhibition of growth of the odor-forming Gram-positive bacteria to be observed is 0.3%, whereby it is however to be noted that a total inhibition is not in all circumstances desirable. All percentage contents which are here given are percentum by weight.
• farnesol can also be employed as a component of perfume compositions, such compositions having a correspondingly high content of farnesol were tested for their bacteriostatic activity. The activity of such farnesol-rich perfume compositions could similarly be clearly shown. Antagonistic effects due to the presence of other components of the perfume composition could not be determined. Since the amount of perfume in cosmetic finished products is normally from about 0.5 to about 1%, a perfume or perfume oil which comprises farnesol as active bacteriostatic must consist of from about 30 to about 60% farnesol. Farnesol as a sesquiterpene alcohol possesses only a relatively weak smell, but has good fixative properties and can thus be employed without reservation in high concentrations as a component of perfume compositions.
• a content of at least 0.15% by weight of farnesol in cosmetic products leads to a good bacteriostatic activity on Gram-positive epidermal bacterial flora.
• a content of at least 0.2% leads to a complete inhibition of the growth of pathogenic Staphylococcus and is sufficient for many purposes, for example for deodorants where a content of 0.2 to 0.5% farnesol is suitable.
• the lower concentration limit is 0.25% farnesol and for cosmetic products with which a substantially complete or complete inhibition of growth of Gram-positive bacteria should be obtained, farnesol should be present at a concentration of 0.3% or more. For practical reasons, at most 1% farnesol would be included in cosmetic products, although basically there is no upper limit.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Dermatology (AREA)
• Emergency Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=6012465

Family Applications (1)

Country Status (13)

Cited By (14)

Families Citing this family (9)

Citations (1)

Family Cites Families (4)

• 1977
  • 1977-06-27 DE DE2728921A patent/DE2728921C3/de not_active Expired
• 1978
  • 1978-03-16 AU AU34219/78A patent/AU3421978A/en active Pending
  • 1978-03-20 CA CA299,289A patent/CA1092978A/en not_active Expired
  • 1978-03-21 AT AT201078A patent/AT361635B/de not_active IP Right Cessation
  • 1978-03-23 DD DD78204381A patent/DD137056A5/xx unknown
  • 1978-04-03 NL NLAANVRAGE7803535,A patent/NL183926C/xx not_active IP Right Cessation
  • 1978-04-03 CH CH356378A patent/CH632926A5/de not_active IP Right Cessation
  • 1978-04-10 JP JP53042030A patent/JPS6042765B2/ja not_active Expired
  • 1978-06-12 US US05/914,723 patent/US4220665A/en not_active Expired - Lifetime
  • 1978-06-14 SE SE7806871A patent/SE444642B/sv unknown
  • 1978-06-19 GB GB7827283A patent/GB2000030B/en not_active Expired
  • 1978-06-22 IT IT7824877A patent/IT1096770B/it active
  • 1978-06-23 FR FR7818860A patent/FR2395752A1/fr active Granted

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents